ECSP13012608A - Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético - Google Patents

Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético

Info

Publication number
ECSP13012608A
ECSP13012608A ECSP13012608A ECSP13012608A EC SP13012608 A ECSP13012608 A EC SP13012608A EC SP13012608 A ECSP13012608 A EC SP13012608A EC SP13012608 A ECSP13012608 A EC SP13012608A
Authority
EC
Ecuador
Prior art keywords
piridin
trifluoro
amino
methyl
acético
Prior art date
Application number
Other languages
English (en)
Inventor
Michael J Girgis
Mahavir Prashad
Paul Allen Sutton
Edwin Bernard Villhauer
Jessica Liang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012608A publication Critical patent/ECSP13012608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a novedosas formas cristalinas del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético, sal sódica, y a su uso en el tratamiento o en la prevención de una condición o de un trastorno asociado con la actividad del DGAT1 en animales, en particular en los seres humanos. También se refiere a procesos para la elaboración de estas formas cristalinas novedosas.
ECSP13012608 2010-10-07 2013-05-07 Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético ECSP13012608A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39088810P 2010-10-07 2010-10-07

Publications (1)

Publication Number Publication Date
ECSP13012608A true ECSP13012608A (es) 2013-07-31

Family

ID=44802409

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012608 ECSP13012608A (es) 2010-10-07 2013-05-07 Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético

Country Status (25)

Country Link
US (2) US8829194B2 (es)
EP (2) EP2625172B1 (es)
JP (1) JP6093703B2 (es)
KR (2) KR101900652B1 (es)
CN (1) CN103153981B (es)
AR (1) AR083317A1 (es)
AU (1) AU2011312185B2 (es)
BR (1) BR112013008355A2 (es)
CA (1) CA2813736C (es)
CL (1) CL2013000929A1 (es)
CO (1) CO6710909A2 (es)
EC (1) ECSP13012608A (es)
ES (2) ES2618411T3 (es)
GT (1) GT201300089A (es)
IL (1) IL225532A0 (es)
MA (1) MA34645B1 (es)
MX (1) MX2013003835A (es)
NZ (1) NZ608557A (es)
PE (1) PE20140337A1 (es)
PL (2) PL2781516T3 (es)
PT (2) PT2625172T (es)
RU (1) RU2612556C2 (es)
SG (1) SG188586A1 (es)
TW (1) TW201217360A (es)
WO (1) WO2012047948A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083317A1 (es) * 2010-10-07 2013-02-13 Novartis Ag Forma cristalina de la sal sodica del acido (4-{4-[5-(6-trifluorometil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, composicion farmaceutica y un proceso para la elaboracion de la modificacion c
CA2844835A1 (en) * 2011-09-12 2013-03-21 Uwe Grether N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
SG11201406526WA (en) * 2012-04-27 2014-11-27 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
US9108956B2 (en) * 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
KR101646716B1 (ko) 2016-02-15 2016-08-08 서성환 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단
MX2021007544A (es) * 2018-12-20 2021-08-11 Merck Sharp & Dohme Llc Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
ATE442365T1 (de) 2003-05-20 2009-09-15 Novartis Pharma Gmbh N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
US20050226906A1 (en) 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
ES2430115T3 (es) * 2006-03-31 2013-11-19 Novartis Ag Inhibidor de DGAT
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
AR083317A1 (es) * 2010-10-07 2013-02-13 Novartis Ag Forma cristalina de la sal sodica del acido (4-{4-[5-(6-trifluorometil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, composicion farmaceutica y un proceso para la elaboracion de la modificacion c

Also Published As

Publication number Publication date
US20130184311A1 (en) 2013-07-18
AU2011312185A1 (en) 2013-04-04
JP6093703B2 (ja) 2017-03-08
EP2625172B1 (en) 2016-12-07
MX2013003835A (es) 2013-06-28
PT2781516T (pt) 2017-03-15
EP2781516A3 (en) 2014-10-15
RU2013120549A (ru) 2014-11-20
BR112013008355A2 (pt) 2016-06-14
ES2618411T3 (es) 2017-06-21
JP2013539755A (ja) 2013-10-28
PE20140337A1 (es) 2014-03-13
CN103153981B (zh) 2017-10-10
NZ608557A (en) 2015-02-27
RU2612556C2 (ru) 2017-03-09
KR101900652B1 (ko) 2018-09-19
CA2813736A1 (en) 2012-04-12
SG188586A1 (en) 2013-04-30
ES2618426T3 (es) 2017-06-21
IL225532A0 (en) 2013-06-27
CN103153981A (zh) 2013-06-12
EP2781516B1 (en) 2016-12-07
US8829194B2 (en) 2014-09-09
EP2625172A1 (en) 2013-08-14
MA34645B1 (fr) 2013-11-02
US20140343102A1 (en) 2014-11-20
GT201300089A (es) 2014-12-30
CA2813736C (en) 2020-03-24
PL2781516T3 (pl) 2017-05-31
CO6710909A2 (es) 2013-07-15
PL2625172T3 (pl) 2017-07-31
WO2012047948A1 (en) 2012-04-12
TW201217360A (en) 2012-05-01
AR083317A1 (es) 2013-02-13
PT2625172T (pt) 2017-03-10
CL2013000929A1 (es) 2013-09-27
AU2011312185B2 (en) 2015-07-02
EP2781516A2 (en) 2014-09-24
KR20180011337A (ko) 2018-01-31
KR20130115277A (ko) 2013-10-21

Similar Documents

Publication Publication Date Title
ECSP13012608A (es) Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CO7240407A2 (es) Formas cristalinas de un modulador del receptor androgénico
EA201890641A3 (ru) Стимуляторы sgc
BR112013024418A2 (pt) materiais ativos para dispositivos eletroópticos e dispositivos eletroópticos
EA201201648A1 (ru) Стимуляторы sgc
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CR20150589A (es) Compuestos de biheteroarilo y usos de los mismos
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
DK2987791T3 (da) 3-(4-(Benzyloxy)phenyl)hex-4-insyre-derivat, egnet til forebyggelse og behandling af metaboliske sygdomme
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
ES2869910T8 (es) Preparación compuesta, que contiene un nuevo derivado de ácido 3-(4-(benciloxi)fenil)hex-4-inoico y otro principio activo, para prevenir o tratar enfermedades metabólicas
UY34385A (es) Ésteres lábiles de agroquímicos para una liberación controlada y reducción del desplazamiento fuera del sitio de acción
CL2016000583A1 (es) Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica.
BRPI1007883A2 (pt) sal, e, cristal.
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
BR112014009165A2 (pt) sal e uso médico
AR101523A1 (es) Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
BR112017008594A2 (pt) derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia
DK3066108T3 (da) 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat